Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Noted Duke Brain Cancer Specialist to Direct Allegheny Health Network Neuro-Oncology Program
  • USA - English


News provided by

Allegheny Health Network

Jun 30, 2015, 11:55 ET

Share this article

Share toX

Share this article

Share toX

Tulika Ranjan, MD
Tulika Ranjan, MD

Pittsburgh, PA (PRWEB) June 30, 2015 -- Tulika Ranjan, MD, a prominent neuro-oncologist from the Duke Brain Tumor Center, has joined Allegheny Health Network (AHN) as Director of its Adult Neuro-Oncology program.

Dr. Ranjan’s clinical and research interests involve the management of primary brain tumors, brain metastases, leptomeningeal disease and the neurological complications of cancer. She has special expertise in the treatment of glioblastoma multiforme (GBM), the most common and aggressive type of malignant primary brain tumor.

I’m excited about the opportunity to develop a pioneering neuro-oncology program that offers patients every resource they need to fight this formidable disease.

Post this

About 50 percent of patients diagnosed with GBM die within one year and 90 percent die within three years. Median survival without treatment is just over four months. Standard treatments for the disease include surgery, radiation and chemotherapy.

Dr. Ranjan was part of the clinical research team at Duke that recently developed a novel therapy for Glioblastoma using the polio virus. The treatment being tested in an ongoing phase 1 study attacks the tumor using an engineered form of the polio virus that is lethal to cancer cells, but harmless to normal cells. Infused directly into the tumor, the virus-based therapy also triggers the body’s immune system to launch an attack against the infected tumor cells.

“Dr. Ranjan is an extremely talented and accomplished oncologist whose unique expertise greatly complements our Network’s already robust cancer and neuroscience programs,” said David Parda, MD, Professor and Chair of the Allegheny Health Network Cancer Institute. “Our team of oncologists, neurologists and neurosurgeons look forward to working collaboratively with Dr. Ranjan to further advance the treatment of brain cancer and help extend and improve the lives of some of our sickest patients.”

AHN’s Cancer Institute is a nationally recognized program that offers the complete spectrum of oncology care, including access to state-of-the-art technologies and new therapies being explored in clinical cancer trials.

Physicians at the Network have participated in many national clinical trials that have provided important information about the pathology and treatment of primary brain tumors, including glioblastoma multiforme and other non-malignant varieties.

In 2010, Allegheny General Hospital was one of just three medical centers nationwide to receive FDA approval to use an investigational medication which turns tumor cells bright red, enabling surgeons to better see the boundaries of the tumor and achieve more complete surgical removal of cancerous tissue.

AGH doctors also were among the first in the country to participate in clinical trials of Tumor Treating Fields (TTFields) therapy, a non-invasive treatment now approved by the FDA for recurrent glioblastoma that slows and reverses tumor growth using low intensity electric fields to inhibit the process by which cancer cells divide and replicate.

“The Departments of Oncology, Neurology and Neurosurgery at AHN have a long history of innovative care for patients with brain cancer and we are very pleased to have a neuro-oncologist and scientist of Dr. Ranjan’s caliber on board to help lead our program into the future,” said James Valeriano, MD, Chair, Department of Neurology, Allegheny Health Network. “Her appointment will greatly enhance our neuro-oncology research efforts and strengthen our capabilities for delivering the best possible care to patients.”

AHN also has a formal affiliation with the Johns Hopkins Sidney Kimmel Cancer Center, a National Cancer Institute-designated comprehensive cancer center, for clinical collaborations, medical education, and a broad range of cancer research initiatives. Dr. Ranjan will collaborate with Dr. Stuart Grossman, a leading clinician and Professor of Oncology, Medicine and Neurosurgery at John Hopkins, to expand and enhance AHN’s neuro-oncology program.

“I’m excited about the opportunity to build upon AHN‘s expert capabilities and develop a pioneering neuro-oncology program that offers patients every resource they need to fight this formidable disease,” Dr. Ranjan said.

Board certified in Neuro-Oncology and Neurology, Dr. Ranjan completed her neurology residency at the University of Medicine and Dentistry of New Jersey and a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center. She earned her medical degree at Sri Krishna Medical College, India.

Dr. Ranjan sees patients at the AGH Cancer Center. Appointments can be scheduled with her by calling 412.359.6220.

Jennifer Davis, Allegheny Health Network, +1 (412) 330-4439, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.